Dental divestment sharpens BioMimetic's focus
This article was originally published in Clinica
Executive Summary
In line with its strategy to focus on the orthopaedics and sports medicine markets, regenerative medicine firm BioMimetic Therapeutics has agreed to sell the remainder of its dental business to Luitpold Pharmaceuticals.